News Sentiment

ABOS sentiment intelligence

Acumen Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.63 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +11.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 11.0% over four weeks
Fair value 0.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 27
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 10
TradingView 5
TradingKey 3
Exec Edge 2
The Manila Times 2
The Globe and Mail 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 12
Analyst action 2
Deals and strategy 2
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
TradingView Direct company coverage

Acumen Pharmaceuticals nominates two EBD candidates, targets mid-2027 IND with 14-40x brain penetration in NHPs

Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) candidates, derived from sabirnetug and ACU234, for development, targeting a mid-2027 IND submission. Preclinical data in NHPs showed 14–40x higher brain antibody levels compared to native antibodies, alongsid

Tone
Positive 70/100
Event
Market update
Published
16 Jun 2026 12:09
Source
TradingView
Stock Titan Direct company coverage

Acumen (NASDAQ: ABOS) advances two EBD Alzheimer’s drug candidates

Acumen Pharmaceuticals (NASDAQ: ABOS) has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer's disease, exercising its option to license and develop them in collaboration with JCR Pharmaceuticals. These candidates utilize JCR's J-

Tone
Positive 70/100
Event
Market update
Published
16 Jun 2026 11:40
Source
Stock Titan
Stock Titan Direct company coverage

Two new antibody designs aim for higher brain delivery in Alzheimer’s

Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer's disease treatment. These candidates combine Acumen's AβO-selective antibodies with JCR Pharmaceuticals' J-Brain Cargo® technology to improve blood-bra

Tone
Positive 74/100
Event
Market update
Published
16 Jun 2026 11:40
Source
Stock Titan
Quiver Quantitative Direct company coverage

Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment

Acumen Pharmaceuticals has nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery (EBD) program for Alzheimer's disease treatment, utilizing JCR Pharmaceuticals' J-Brain Cargo® technology. These candidates aim for improved brain penetration and sa

Tone
Positive 67/100
Event
Market update
Published
16 Jun 2026 11:40
Source
Quiver Quantitative